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ABSTRACT
A pneumothorax can be primary or secondary. A high proportion of patients with secondary spontaneous
pneumothorax are the elderly who are in poor general condition due to their impaired cardiac and pulmo-
nary functions as well as due to other complications. Therefore, it may be difficult for these patients to
undergo surgical procedures; in addition, the elderly may be at high risk for postoperative pulmonary fistula
due to severe adhesions and emphysema complications. These non-operative and high-risk cases may be
treated with pleurodesis (a procedure that involves instillation of a chemical or irritant into the thoracic cav-
ity through an injection), bronchoscopic bronchial embolisation, or other procedures. In Japan, no device is
currently approved for performing pleurodesis, but an approval of one device is expected soon. This will be
an open-label, single-arm multicentre study conducted among 30 patients with secondary intractable pneu-
mothorax who are not indicated to undergo surgery. The primary endpoint will be presence or absence of
chest tube removal. The secondary endpoints will be the disappearance/decrease of air leakage, grade of
dyspnoea, and duration of drainage. This study will assess the safety and efficacy of sterile graded talc pleu-
rodesis in patients with secondary intractable pneumothorax.
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Pneumothorax is defined as the leakage of air into the
pleural cavity through a hole in the visceral pleura. It is
classified as spontaneous, traumatic, or iatrogenic pneu-
mothorax according to the cause. There are two types of
spontaneous pneumothorax: primary and secondary.
Secondary spontaneous pneumothorax is caused by
underlying pulmonary diseases, such as chronic obstruc-
tive pulmonary disease (COPD), lung cancer, and
interstitial pneumonia. Therefore, unlike primary spon-
taneous pneumothorax, in secondary pneumothorax, the
respiratory reserve capacity is often decreased. In
addition, secondary pneumothorax is usually more
severe than primary spontaneous pneumothorax; this is
because the secondary pneumothorax itself causes an
additional decline of the pulmonary function.
The proportion of the elderly among patients with sec-
ondary spontaneous pneumothorax is high. These eld-
erly patients are usually in a poor general condition due
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their low cardiac and pulmonary functions as well as due
to other complications. Therefore, it may be difficult for
these patients to undergo surgical procedures, and they
may be at a higher risk for postoperative pulmonary fis-
tula due to severe adhesions and emphysema complica-
tions. These patients, who cannot undergo surgical
procedures, are diagnosed to have intractable pneumo-
thorax5). Such non-operative and high-risk cases are the
targets for pleurodesis (which involves instillation of a
chemical or irritant into the thoracic cavity through an
injection), bronchoscopic bronchial embolisation, or
other procedures2).
In Japan, a bronchial blocker made of silicone, the
Endobronchial Watanabe Spigot (EWS), was approved in
January 2013 to be manufactured and marketed as a
medical device for the treatment of secondary intractable
pneumothorax in patients not indicated for surgery.
Some patients cannot tolerate insertion of an EWS
through bronchoscopy; these patients should be treated
with pleurodesis. However, no device is currently
approved for performing pleurodesis, and an approval of
one device is expected soon.
Talc, a pleurodesis agent, has been approved to be
manufactured and marketed as a medical device in
Europe. It is indicated for the treatment of chronic
pleurisy (mainly malignant), spontaneous pneumo-
thorax, and a few other diseases. However, in Japan, talc
(Unitalc®, Nobelpharma, Nihonbashi-kobunacho, Tokyo,
Japan) has been approved only for the prevention of the
re-accumulation of malignant pleural effusion3); treat-
ment of spontaneous pneumothorax with talc has not
been approved.
Treatment of spontaneous pneumothorax with talc is
recommended in Europe and the United States. The
guideline of the British Thoracic Society (BTS)4) states
that pleurodesis by administration of talc using the
slurry method is the desired treatment for patients who
do not want to undergo video-assisted thoracic surgery
(VATS); however, administration of talc (using the
spraying method) with VATS is the optimal treatment
method for spontaneous pneumothorax. The American
College of Chest Physicians (ACCP) guideline1) recom-
mends injection of talc slurry through a chest tube as the
preferred method of pleurodesis; however, the spray
method is an acceptable treatment in the prevention of
recurrent secondary spontaneous pneumothorax.
According to these guidelines, pleurodesis with talc is an
internationally established treatment for spontaneous
pneumothorax (including secondary pneumothorax).
Therefore, we planned an investigator-initiated study of
talc in patients with secondary intractable pneumothorax
who have no indications for surgery. We aim to deter-
mine the efficacy of talc, obtain approval, and develop its
use in patients with spontaneous pneumothorax in
Japan. The estimated total number of patients with sec-
ondary intractable pneumothorax in Japan is 2,000;
therefore, this treatment will be applied to a rare disease
(RD).
MATERIALS AND METHODS
Ethics Committee Procedure and Consent
Study approvals will be obtained from the internal
review boards of each participating institution prior to
the implementation of the study.
Written informed consent will be obtained from every
patient prior to the participation in the trial.
Study Design Eligibility criteria
Inclusion criteria
The inclusion criteria for this study will be as follows:
1. A diagnosis of pneumothorax by chest radiography.
2. Presence of any underlying disease that causes pneu-
mothorax.
3. Presence of air leakage that has lasted for more than 7
days without a response to thoracic drainage at the
time of case registration.
4. Not being appropriate for surgery, having a high risk
for anaesthetic and surgical complications due to a low
pulmonary function or other causes, or having experi-
enced a relapse without surgery, with an expected low
therapeutic benefit of a second surgery.
5. Age of 20 years or older at the time of consent.
6. Provision of free written consent for the participation
in this study.
Exclusion criteria
Exclusion criteria for this study will be as follows:
 1. Spontaneous, traumatic, or iatrogenic pneumothorax.
 2. History of hypersensitivity to talc.
 3. Presence of severe complications due to an infection.
 4. Treatment for heart failure at the time of consent.
 5. History of myocardial infarction within 30 days of
consent.
 6. Advanced blood coagulation disorders (platelet count
> 50,000/μl)
 7. Requirement for bilateral pleurodesis.
 8. History of postoperative pulmonary fistula.
 9. Use of systemic corticosteroids (equivalent to 10
mg/day or more of prednisolone) at the time of case
registration.
10. Clinical expectation of a good response by bronchial
embolisation therapy using the EWS only.
11. Pregnancy, breastfeeding, wishing to become preg-
nant during the observation period, or inability to
control conception.
12. Participation in other trials within 6 months before
consent.
13. Unsuitability for participation in this study as deter-
mined by the principal investigator or sub-
investigators.
Dosage and administration
Four grams of the investigational drug will be sus-
pended in 50 ml of physiological saline solution; the sus-
pension will be aspirated into a syringe and slowly
injected into the pleural cavity through a drug injection
tube.
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Then, 50 ml of physiological saline will be injected
using the same method in order to ensure the suspension
reaches the pleural cavity.
Negative pressure will be applied using a continuous
low-pressure aspirator to prevent drainage of the sus-
pension.
Pleurodesis and drainage of investigational drug
suspension
The patient’s posture will be changed after every 30
minutes (for approximately 2 hours) to ensure the sus-
pension is sufficiently distributed throughout the pleural
cavity. The range of postures will be as follows: supine
position → lateral position on the unaffected side → and
lateral position on the affected side + prone position.
Pleurodesis will be completed 2 hours after the injection
of the investigational drug suspension. A negative pres-
sure suction of –20 cm H2O will be applied as a guide.
Additional administration of the investigational
drug
If it will be judged that the effect of pleurodesis by
administration of the investigational drug is insufficient,
pleurodesis will be repeated by additional administration
of the drug. Additional investigational treatments will be
administered only once within 30 days at intervals of 7
days or longer (treatment on the same day of the week is
possible) and before the removal of the chest tube.
Because the risk of acute respiratory distress syndrome
(ARDS) may increase due to the additional administra-
tion of the investigational drug, the need for this addi-
tional treatment will be carefully determined according
to the patient’s condition.
Observation Period
The observation period will be from the date of provi-
sion of a written consent to 30 days after the pleurodesis
treatment. If additional administration of the investiga-
tional drug will be performed, the observation will be
extended up to 30 days after retreatment with pleurode-
sis (Figure 1).
Follow-up
If patients leave the hospital by 6 months after the end
of the observation period, the following items will be
examined on discharge date:
• Presence or absence of hospital discharge (discharge
date and reason for discharge in the case of presence)
• Presence or absence of chest tube removal
• Presence or absence of continuous treatment for pneu-
mothorax
• Others, including death
Patients who will not be discharged will be examined
at 6 months.
Endpoints
Primary efficacy endpoints
1. Presence or absence of chest tube removal
This will be judged to be “present” if the chest tube is
removed within 30 days after pleurodesis or retreatment
with pleurodesis. The criterion for the removal of the
chest tube is the disappearance of air leakage from the
chest tube, and lung re-expansion will be confirmed by
chest radiography. If pleurodesis retreatment is per-
formed due to an insufficient effect, the evaluation will
be done after the retreatment. If the chest tube is placed
and removed more than once during the observation
period, only the first removal will be judged as “present”,
and no further judgment will be made. The proportion of
success will be calculated as follows: the number of
patients with chest tube removal divided by the number
of population of efficacy.
Secondary efficacy endpoints
1. Disappearance/Decrease of air leakage
The degree of air leakage before pleurodesis (within 7
days), after pleurodesis (or after retreatment with pleu-
rodesis), and when removing the chest tube (or at the
time of discontinuation or completion) will be evaluated.
The degree of air leakage will determined according to
the following grades:
-Disappearance - No air leakage is recognised
-Mild - Air leakage is recognised only when coughing
-Moderate - Air leakage at the time of expiration
-Severe - Sustained air leakage is recognised at the
time of expiration and inspiration
2. Grade of dyspnoea according to the modified British
Medical Research Council (mMRC) dyspnoea scale
(Table 1)
The degree of dyspnoea according to the mMRC dysp-
noea scale before pleurodesis (within 7 days), after pleu-
rodesis (or after a retreatment with pleurodesis), and
when removing the chest tube (or at the time of discon-
tinuation or completion) will be evaluated.
3. Duration of drainage
The duration of drainage will be defined as the time (in
days) from pleurodesis until the first removal of the chest
tube. If the chest tube will not be removed, it will be cen-
sored at the final observation.
Safety endpoints
Adverse events
Adverse events and side effects occurring during the
observation period of 30 days after the administration of
the investigational drugs (in the case of addition of the
investigational drug, 30 days after the additional admin-
istration) will be evaluated. The evaluation of adverse
events will be performed by using the common terminol-
ogy criteria for adverse events (CTCAE) v4.03; the
adverse events will be listed, and the severity of each
event will be graded.
Safety Considerations
During the study, the data and safety monitoring
board will deliberate (and recommend on the continua-
tion/change or termination of the study) in response to a
consultation from the principal investigator in the fol-
lowing cases:
• Occurrence of serious adverse events
• Occurrence of problems that require an early termina-
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Informed consent 
Screening (registration) 
Administration of talc 
(pleurodesis) 
Removal of chest 
tube 
Observation in follow-up study 
Chest tube has 
not been removed 
・Chest tube has been removed 
・Discharge, transfer, mortality 
・Discontinuation of the study 
Termination of the follow-up 
study 
Termination of observation 30 days after 
pleurodesis 
Termination of the study 
 
Evaluation of efficacy at the time of 
removal 
Observation period 
 
Hospital discharge or 6 
months, whichever is 
shorter 
Figure 1. Study design
Table 1. mMRC dyspnoea scale
Grade Description of Breathlessness
Grade 0 I only get breathless with strenuous exercise
Grade 1 I get short of breath when hurrying on level ground or walking up a slight hill
Grade 2 On level ground, I walk slower than people of the same age because of breathlessness, or I
have to stop for breath when walking at my own pace on level ground
Grade 3 I stop for breath after walking about 100 yards or after a few minutes on level ground
Grade 4 I am too breathless to leave the house or I am breathless when dressing
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tion of the study
• Any other occurrence that the principal investigator
requires deliberation by the data and safety monitoring
board
Statistical Considerations
Sample size
Outcomes of treatment in patients with secondary
pneumothorax who are not indicated for surgery, have
not been published. Therefore, medical records of
patients who were discharged from the Nagoya Medical
Center between January 2010 and September 2014 after
undergoing treatment with autologous blood adhesions
due to a pneumothorax were analysed. The number of
patients was 30, and the number of procedures was 35
because of multiple operations. The patients had under-
gone various treatments, such as multiple injections
(median, 2 injections; range: 1–10) and EWS use (4
cases). If the number of autologous blood injections was
limited to 2 in a group similar to this study group, the
number of subjects required will be 14.
The proportion of catheter removal at 28 days follow-
ing treatment with autologous blood alone was 43%
(6/14) in patients who had received up to two injections
and 43% (3/7) in subjects that had received one injec-
tion. Therefore, 43% will be considered the threshold for
success. However, due to the small number of patients,
the threshold was set at 36%, a mean of 43% and 30%,
which was the threshold in the clinical study to obtain
approval of EWS. The threshold is consistent with the
proportion of success clinically experienced in the dis-
ease. The expected proportion of success was set at 63%
in anticipation of an improvement of 20% or more.
Accordingly, when the expected proportion is 63%, and
the threshold is 36%, the calculated number of required
patients is 27 based on the binomial distribution, with a
one-sided significance level of 2.5%, and statistical
power of 80%. In anticipation of dropouts, the sample
size was set at 30.
Statistical analysis
Analysis set
All patients who will receive the investigational drug
will be comprise the full-analysis set (FAS). Within the
FAS, an analysis set that does not have a serious protocol
violation, satisfies the protocol, and can evaluate the effi-
cacy is defined as the per-protocol set (PPS). In this
study, the FAS will be the primary analysis set for effi-
cacy. Patients who received the investigational drug will
be analysed for the safety of the drug.
Primary endpoint analysis
The proportion of success will be calculated, and its
exact confidence interval will be estimated using the
binomial distribution. The probability less than or equal
to the threshold (36%) of the distribution will be calcu-
lated; a binomial distribution is assumed for the
observed proportion of success.
Secondary endpoint analysis
Change in the degree of disappearance/decrease of air
leakage from before pleurodesis to 30 days after pleurod-
esis will be analysed using the Wilcoxon signed-rank
test. Change in the degree of dyspnoea from before pleu-
rodesis to 30 days after pleurodesis (or the time of chest
tube removal) will be analysed using the Wilcoxon
signed-rank test. A Kaplan-Meier curve for the duration
of drainage will be created.
Organisation Structure
This study will be conducted at 7 institutions (Appen-
dix 1). HS, HK, NM, NT, MM, OK, and AB will supervise
the work related to this study as investigators, managers
and instructors. They will also serve as managers of the
team of sub-investigators and study cooperators. AK will
be responsible for statistical analysis in this study. AS
will be responsible for case registration, data manage-
ment and study monitoring.
DISCUSSION
Patients with secondary intractable pneumothorax
often required chest drainage for a long time. Some of
the non-operative patients cannot tolerate insertion of
EWS through bronchoscopy. Approval of talc pleurodesis
will benefit such patients.
Talc, which is a pleurodesis agent, has been approved
in Europe and United States as a medical device for the
treatment of chronic pleurisy (mainly malignant), spon-
taneous pneumothorax, and other conditions for which
pleurodesis is indicated.
However, in Japan, talc has been approved only for the
prevention of re-accumulation of malignant pleural effu-
sion; its use in the treatment of spontaneous pneumo-
thorax has not been approved. This study aims to expand
the indications of talc in Japan by assessing its safety
and efficacy in secondary intractable pneumothorax.
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